/ Published in Blog

Fertility preservation in endometrial cancer patients: options, challenges and perspectives

Fertility preservation in endometrial cancer patients

Milan Terzic 1 2 3 4, Melanie Norton 5, Sanja Terzic 2, Gauri Bapayeva 1, Gulzhanat Aimagambetova 6 7

Affiliations + expand
PMID: 32419842 PMCID: PMC7221125 DOI: 10.3332/ecancer.2020.1030
Free PMC article

Abstract

Several different approaches have been designed by physicians in order to preserve fertility in younger patients with endometrial carcinoma. There are various options offering different advantages, but hysteroscopic resection of pathologic endometrial tissue with placement of a Levonorgestrel Intrauterine Device has proven to be the most successful in allowing patients to conceive and give birth afterwards. However, conservative treatments should only be considered in patients with low-grade and low-stage endometrial tumours. There are many published studies which have sought out a preferable approach to treating endometrial cancer whilst preserving fertility. However, more research on this matter is needed to allow a better understanding as to which techniques/approaches are optimal. In this review, we will summarise the current available treatment options for endometrial cancer in patients of reproductive age.

Keywords: IUD; conservative management intrauterine system; endometrial cancer; fertility preservation; hysteroscopy.

Conflict of interest statement

The authors declare that they have no conflict of interests with respect to this paper.

References

  1. Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(2):170–199. doi: 10.6004/jnccn.2018.0006. – DOI – PubMed
  2. Wei J, Zhang W, Feng L, et al. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore) 2017;96(37):e8034. doi: 10.1097/MD.0000000000008034. – DOI – PMC – PubMed
  3. Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110(4):354–361. doi: 10.1093/jnci/djx214. – DOI – PubMed
  4. Casarin J, Bogani G, Serati M, et al. Presence of glandular cells at the preoperative cervical cytology and local recurrence in endometrial cancer. Int J Gynecol Pathol. 2019. – DOI – PubMed
  5. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366(9484):491–505. doi: 10.1016/S0140-6736(05)67063-8. – DOI – PubMed
  6. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol. 1991;41(1):1–6. doi: 10.1016/0090-8258(91)90246-2. – DOI – PubMed
  7. Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299(2):299–315. doi: 10.1007/s00404-018-5006-z. – DOI – PubMed
  8. Guo S, Yang J, Wu M, et al. Clinical value screening, prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma: a study based on the Cancer Genome Atlas (TCGA), and bioinformatics analysis. Pathol Res Pract. 2019;215(5):1003–1011. doi: 10.1016/j.prp.2019.02.007. – DOI – PubMed
  9. Resnick KE, Hampel H, Fishel R, et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114:128–134. doi: 10.1016/j.ygyno.2009.03.003. – DOI – PMC – PubMed
  10. Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol. 2002;99(4):663–670. – PubMed
  11. Cignini P, Vitale SG, Laganà AS, et al. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg. 2017;69(1):75–82. doi: 10.1007/s13304-017-0418-z. – DOI – PubMed
  12. De Franciscis P, Riemma G, Schiattarella A, et al. Concordance between the hysteroscopic diagnosis of endometrial hyperplasia and histopathological examination. Diagnostics (Basel) 2019;9(4) pii: E142. – PMC – PubMed
  13. Chiofalo B, Mazzon I, Di Angelo Antonio S, et al. Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies: results from a large multicenter cohort study. J Minim Invasive Gynecol. 2019. pii: S1553-4650(19)30365-6. – PubMed
  14. Clark TJ, Voit D, Gupta JK, et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288(13):1610–1621. doi: 10.1001/jama.288.13.1610. – DOI – PubMed
  15. Clark TJ, Mann CH, Shah N, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG. 2002;109(3):313–321. doi: 10.1111/j.1471-0528.2002.01088.x. – DOI – PubMed
  16. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi: 10.1016/S0140-6736(15)00130-0. – DOI – PubMed
  17. Frumovitz M, Singh DK, Meyer L, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004;95(3):463–468. doi: 10.1016/j.ygyno.2004.07.016. – DOI – PubMed
  18. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi: 10.1016/0090-8258(83)90111-7. – DOI – PubMed
  19. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851–1856. doi: 10.1007/s10552-010-9612-8. – DOI – PMC – PubMed
  20. Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7(4):227–242. doi: 10.1677/erc.0.0070227. – DOI – PubMed
  21. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607. doi: 10.1200/JCO.2012.48.2596. – DOI – PMC – PubMed
  22. Levine D, Getz G, Gabriel S. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. – DOI – PMC – PubMed
  23. Kim SI, Lee JW, Lee N, et al. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the cancer genome atlas data. BMC Cancer. 2018;18(1):494. doi: 10.1186/s12885-018-4429-z. – DOI – PMC – PubMed
  24. Barra F, Evangelisti G, Ferro Desideri L. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2013;28(2):131–142. doi: 10.1080/13543784.2018.1558202. – DOI – PubMed
  25. Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–116. doi: 10.1097/AOG.0000000000002390. – DOI – PMC – PubMed
  26. Vitale SG, Rossetti D, Tropea A, et al. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg. 2017;69(1):29–34. doi: 10.1007/s13304-017-0419-y. – DOI – PubMed
  27. Rossetti D, Bogani G, Carnelli M, et al. Efficacy of IVF following conservative management of endometrial cancer. Gynecol Endocrinol. 2014;30(4):280–281. doi: 10.3109/09513590.2014.892065. – DOI – PubMed
  28. Laganà AS, La Rosa VL, Rapisarda AM, et al. Comment on: “Needs and priorities of women with endometrial and cervical cancer”. J Psychosom Obstet Gynaecol. 2017;38(1):85–86. doi: 10.1080/0167482X.2016.1244186. – DOI – PubMed
  29. Franchi M, Garzon S, Zorzato PC, et al. PET-CT scan in the preoperative workup of early stage intermediate- and high-risk endometrial cancer. Minim Invasive Ther Allied Technol. 2019;6:1–8. doi: 10.1080/13645706.2019.1624576. – DOI – PubMed
  30. Scalici J, Laughlin BB, Finan MA, et al. The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol. 2015;136:512–515. doi: 10.1016/j.ygyno.2014.11.014. – DOI – PubMed
  31. Boggess JF, Gehrig PA, Cantrell L, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obst Gynecol. 2008;199(4):360.e1–360.e9.. doi: 10.1016/j.ajog.2008.08.012. – DOI – PubMed
  32. Vitale SG, Valenti G, Gulino FA, et al. Surgical treatment of high stage endometrial cancer: current perspectives. Updates Surg. 2016;68(2):149–154. doi: 10.1007/s13304-015-0340-1. – DOI – PubMed
  33. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331–5336. doi: 10.1200/JCO.2009.22.3248. – DOI – PMC – PubMed
  34. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30:695–700. doi: 10.1200/JCO.2011.38.8645. – DOI – PMC – PubMed
  35. Janda M, Gebski V, Davies LC, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA. 2017;317:1224–1233. doi: 10.1001/jama.2017.2068. – DOI – PubMed
  36. Zanagnolo V, Achilarre MT, Maruccio M, et al. Might robotic-assisted surgery become commonplace in endometrial cancer treatment? Expert Rev Anticancer Ther. 2018;18(6):507–509. doi: 10.1080/14737140.2018.1469981. – DOI – PubMed
  37. Park DA, Lee DH, Kim SW, et al. Comparative safety and effectiveness of robot-assisted laparoscopic hysterectomy versus conventional laparoscopy and laparotomy for endometrial cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2016;42:1303–1314. doi: 10.1016/j.ejso.2016.06.400. – DOI – PubMed
  38. Centurioni MG, Barra F, Gustavino C, et al. Sentinel-node mapping by intraoperative near-infrared fluorescence in the robotic surgical treatment of endometrial cancer. J Gynecol Surg. 2019;35(4):205–207. doi: 10.1089/gyn.2018.0106. – DOI
  39. Hogberg T, Signorelli M, De Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer. 2010;46(13):2422–2431. doi: 10.1016/j.ejca.2010.06.002. – DOI – PMC – PubMed
  40. Rossetti D, Vitale SG, Gulino FA, et al. Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers. Eur J Gynaecol Oncol. 2016;37(5):657–661. – PubMed
  41. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477–482. doi: 10.1016/j.ygyno.2012.01.003. – DOI – PubMed
  42. Hubbs JL, Saig RM, Abaid LN, et al. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol. 2013;121:1172–1180. doi: 10.1097/AOG.0b013e31828d6186. – DOI – PubMed
  43. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102(4):718–725. – PubMed
  44. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90(3):434–440. doi: 10.1016/S0029-7844(97)00297-4. – DOI – PubMed
  45. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: report of seven cases and review of the literature. Cancer. 1997;79(2):320–327. doi: 10.1002/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2. – DOI – PubMed
  46. Eftekhar Z, Izadi-Mood N, Yarandi F, et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009;19(2):249–252. doi: 10.1111/IGC.0b013e31819c5372. – DOI – PubMed
  47. Lowe MP, Bender D, Sood AK, et al. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril. 2002;77(1):188–189. doi: 10.1016/S0015-0282(01)02937-5. – DOI – PubMed
  48. Baker J, Obermair A, Gebski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125:263–270. doi: 10.1016/j.ygyno.2011.11.043. – DOI – PubMed
  49. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22(7):1953–1958. doi: 10.1093/humrep/dem088. – DOI – PubMed
  50. Laganà AS, Palmara V, Granese R, et al. Desogestrel versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation. Gynecol Endocrinol. 2014;30(11):794–797. doi: 10.3109/09513590.2014.929658. – DOI – PubMed
  51. Sansone A, De Rosa N, Giampaolino P, et al. Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study. Arch Gynecol Obstet. 2018;298(4):731–736. doi: 10.1007/s00404-018-4851-0. – DOI – PubMed
  52. Laganà AS, Giacobbe V, Triolo O, et al. Dienogest as preoperative treatment of submucous myomas for hysteroscopic surgery: a prospective, randomized study. Gynecol Endocrinol. 2016;32(5):408–411. doi: 10.3109/09513590.2015.1128409. – DOI – PubMed
  53. Signorelli M, Caspani G, Bonazzi C, et al. Fertility‐sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single‐institution experience of 21 cases. BJOG. 2009;116(1):114–118. doi: 10.1111/j.1471-0528.2008.02024.x. – DOI – PubMed
  54. Laganà AS, Vitale SG, Granese R, et al. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol. 2017;13(6):593–596. doi: 10.1080/17425255.2017.1297421. – DOI – PubMed
  55. Laganà AS, Vitale SG, Muscia V, et al. Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review. Arch Gynecol Obstet. 2017;295(3):661–667. doi: 10.1007/s00404-016-4244-1. – DOI – PubMed
  56. Wang CB, Wang CJ, Huang HJ, et al. Fertility‐preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94(8):2192–2198. doi: 10.1002/cncr.10435. – DOI – PubMed
  57. Mehasseb MK, Latimer JA. Controversies in the management of endometrial carcinoma: an update. Obstet Gynecol Int. 2012;2012:676032. doi: 10.1155/2012/676032. – DOI – PMC – PubMed
  58. Dhar KK, NeedhiRajan T, Koslowski M, et al. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97(3):924–927. doi: 10.1016/j.ygyno.2004.10.031. – DOI – PubMed
  59. Fan Z, Li H, Hu R, et al. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer. 2018;28(2):385–393. doi: 10.1097/IGC.0000000000001164. – DOI – PubMed
  60. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95(3):762–764. doi: 10.1016/j.ygyno.2004.09.010. – DOI – PubMed
  61. Kim MK, Seong SJ, Lee TS, et al. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009) Jpn J Clin Oncol. 2012;42(12):1215–1218. doi: 10.1093/jjco/hys171. – DOI – PubMed
  62. Pronin SM, Novikova OV, Andreeva JY, et al. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer. 2015;25(6):1010–1014. doi: 10.1097/IGC.0000000000000467. – DOI – PubMed
  63. Zhou H, Cao D, Yang J, et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer. 2017;27(6):1178–1182. doi: 10.1097/IGC.0000000000001008. – DOI – PubMed
  64. Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93(4):1286–1289. doi: 10.1016/j.fertnstert.2008.12.009. – DOI – PubMed
  65. Laurelli G, Di Vagno G, Scaffa C, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120(1):43–46. doi: 10.1016/j.ygyno.2010.10.004. – DOI – PubMed
  66. Giampaolino P, Di Spiezio Sardo A, Mollo A, et al. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. J Minim Invasive Gynecol. 2019;26(4):648–656. doi: 10.1016/j.jmig.2018.07.001. – DOI – PubMed